ArticleLeukemia2014

B-cell receptor pathway inhibitors affect CD20 levels and impair antitumor activity of anti-CD20 monoclonal antibodies.

K Bojarczuk et al.PubMed ↗Publisher ↗

No numbers read from the abstract.